KILITCH DRUGS(I)
Kilitch Drugs(I) Share Price
Kilitch Drugs(I) Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in KILITCH DRUGS(I)
Start SIPKilitch Drugs(I) Investment Rating
-
Master Rating:
-
Kilitch Drugs India has an operating revenue of Rs. 128.06 Cr. on a trailing 12-month basis. An annual revenue growth of 65% is outstanding, Pre-tax margin of 8% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 32 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C+ which is evident from recent supply seen, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 24 | 32 | 31 | 23 | 20 | 21 |
| Operating Expenses Qtr Cr | 20 | 28 | 28 | 21 | 17 | 21 |
| Operating Profit Qtr Cr | 3 | 4 | 3 | 2 | 2 | 0 |
| Depreciation Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Qtr Cr | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax Qtr Cr | 1 | 1 | 1 | 0 | 1 | 0 |
| Net Profit Qtr Cr | 3 | 3 | 3 | 2 | 3 | 1 |
Kilitch Drugs(I) Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 168.21
- 50 Day
- 167.25
- 100 Day
- 170.37
- 200 Day
- 182.67
- 20 Day
- 168.96
- 50 Day
- 166.8
- 100 Day
- 163.82
- 200 Day
- 182.81
Kilitch Drugs(I) Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 170.1 |
| Second Resistance | 175.8 |
| Third Resistance | 180.35 |
| RSI | 49.64 |
| MFI | 59.49 |
| MACD Single Line | 0.94 |
| MACD | 0.3 |
| Support | |
|---|---|
| First Resistance | 159.85 |
| Second Resistance | 155.31 |
| Third Resistance | 149.6 |
Kilitch Drugs(I) Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 6,185 | 311,910 | 50.43 |
| Week | 9,997 | 646,906 | 64.71 |
| 1 Month | 15,718 | 979,053 | 62.29 |
| 6 Month | 11,884 | 710,927 | 59.82 |
Kilitch Drugs(I) Result Highlights
Kilitch Drugs(I) Synopsis
NSE-Medical-Diversified
Kilitch Drugs(I) is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 70.02 Cr. and Equity Capital is Rs. 15.49 Cr. for the Year ended 31/03/2021. Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718.| Market Cap | 261 |
| Sales | 109 |
| Shares in Float | 0.50 |
| No of funds | 1 |
| Yield | 0.51 |
| Book Value | 1.47 |
| U/D Vol ratio | 0.8 |
| LTDebt / Equity | |
| Alpha | 0.06 |
| Beta | 0.83 |
Kilitch Drugs(I)
| Owner Name | Jun-22 | Mar-22 | Dec-21 | Sep-21 |
|---|---|---|---|---|
| Promoters | 68.25% | 68.25% | 68.25% | |
| Foreign Portfolio Investors | 0.03% | |||
| Financial Institutions/ Banks | ||||
| Individual Investors | 27.73% | 27.59% | 27.28% | |
| Others | 4.02% | 4.16% | 4.44% |
Kilitch Drugs(I) Management
| Name | Designation |
|---|---|
| Mr. Mukund P Mehta | Managing Director |
| Mr. Bhavin Mukund Mehta | Whole Time Director |
| Mrs. Mira B Mehta | Whole Time Director |
| Mr. Hemang Engineer | Independent Director |
| Mr. Venkita Subramanian Rajan | Independent Director |
| Prof. Vasudev Krishna Murti | Independent Director |
Kilitch Drugs(I) Forecast
Price Estimates
Kilitch Drugs(I) Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-08-10 | Quarterly Results | |
| 2022-05-26 | Audited Results | |
| 2022-02-14 | Quarterly Results | |
| 2021-11-12 | Quarterly Results | |
| 2021-08-13 | Quarterly Results |
Kilitch Drugs(I) FAQs
What is Share Price of Kilitch Drugs(I) ?
Kilitch Drugs(I) share price is ₹168 As on 30 September, 2022 | 02:06
What is the Market Cap of Kilitch Drugs(I) ?
The Market Cap of Kilitch Drugs(I) is ₹262.6 Cr As on 30 September, 2022 | 02:06
What is the P/E ratio of Kilitch Drugs(I) ?
The P/E ratio of Kilitch Drugs(I) is 31.8 As on 30 September, 2022 | 02:06
What is the PB ratio of Kilitch Drugs(I) ?
The PB ratio of Kilitch Drugs(I) is 1.9 As on 30 September, 2022 | 02:06